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Editor’s key points
† Oxidative stress and
mitochondrial dysfunction
are key to the
pathophysiology of sepsis.
† The effects of
antioxidants targeted
to mitochondria on
inflammation, oxidative
stress, and organ
dysfunction were tested
in a rat model of acute
sepsis.
† Antioxidant treatment
reduced mitochondrial
damage, sepsis-induced
inflammation, and organ
dysfunction, a positive
finding that should be
tested in clinical trials.
Background. Sepsis-induced organ failure is the major cause of death in critical care units,
and is characterized by a massive dysregulated inflammatory response and oxidative stress.
We investigated the effects of treatment with antioxidants that protect mitochondria
(MitoQ, MitoE, or melatonin) in a rat model of lipopolysaccharide (LPS) plus peptidoglycan
(PepG)-induced acute sepsis, characterized by inflammation, mitochondrial dysfunction
and early organ damage.
Methods. Anaesthetized and ventilated rats received an i.v. bolus of LPS and PepG followed
by an i.v. infusion of MitoQ, MitoE, melatonin, or saline for 5 h. Organs and blood were then
removed for determination of mitochondrial and organ function, oxidative stress, and key
cytokines.
Results. MitoQ, MitoE, or melatonin had broadly similar protective effects with improved
mitochondrial respiration (P,0.002), reduced oxidative stress (P,0.02), and decreased
interleukin-6 levels (P¼0.0001). Compared with control rats, antioxidant-treated rats had
lower levels of biochemical markers of organ dysfunction, including plasma alanine
amino-transferase activity (P¼0.02) and creatinine concentrations (P,0.0001).
Conclusions. Antioxidants that act preferentially in mitochondria reduce mitochondrial
damage and organ dysfunction and decrease inflammatory responses in a rat model of
acute sepsis.
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Although outcomes have improved, the overall mortality of
sepsis remains at 31% overall, and over 70% in those
patients who go on to develop sepsis-induced multiple
organ failure.1 The hallmark of sepsis is a dysregulated and
overwhelming inflammatory response, characterized by
massive cytokine release, oxidative stress, and mitochondrial
dysfunction. Mitochondria are both sites of reactive oxygen
species (ROS) production, and targets of ROS-mediated
damage, resulting in mitochondrial dysfunction.2 3 During
sepsis, antioxidant defences are overwhelmed, and ROS
cause cellular damage, contributing to organ dysfunction.4 5
Antioxidants acting specifically in mitochondria might be
beneficial in combating the inflammation and oxidative
stress seen in sepsis.6 7 MitoQ and MitoE are antioxidants
attached to a lipophilic cation that accumulate several
hundred-fold within mitochondria due to the negative
charge inside mitochondria, delivering ubiquinol or tocoph-
erol, respectively.8 Endogenous melatonin is primarily recog-
nized for regulation of the sleep–wake cycle, but at high
doses, it has potent antioxidant activity9 and is able to
enter all cell compartments including mitochondria. The
metabolites of melatonin and products from its reactions
with oxidant species also have antioxidant activity.10 11
We have reported previously that in endothelial cells
treated with lipopolysaccharide (LPS) and peptidoglycan G
(PepG) to mimic the cellular responses seen during sepsis,
MitoQ and MitoE decreased cytokine responses.12 13 Mela-
tonin and its main metabolite 6-hydroxymelatonin also
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reduced cytokine responses, prevented mitochondrial dys-
function, and protected endogenous antioxidants in the
same model.11 We have also shown in a small pilot study
that MitoQ administration in rats given LPS/PepG appeared
protective.12 We hypothesized that MitoE and melatonin
may have a similar beneficial effect in rats treated with LPS
and PepG. In this proof-of-concept study, we investigated
the effects of treatment with MitoQ, MitoE, or melatonin on
biomarkers of organ damage, cytokine responses, oxidative
damage, and mitochondrial function after administration of
LPS from Escherichia coli plus PepG from Staphylococcus
aureus in rats. This model reproducibly creates an inflamma-
tory response, with mitochondrial dysfunction and early
changes in organ function also seen in patients with sepsis.14
Methods
Animals
These studies were performed in accordance with UK Home
Office regulations and all animals remained anaesthetized
to a nociceptive stimulus throughout. Adult male Sprague–
Dawley rats (median weight 463 g) were used and were
maintained on normal rat chow. Animals were randomly
pre-assigned, using sealed envelopes, to one of the eight
experimental treatment groups (n¼5–8 per group).
Anaesthesia was induced with 5% isoflurane in oxygen in a
tank then continued using 2–3% isoflurane and a nose cone
while a tracheostomy was performed. Adequate anaesthesia
was ascertained by lack of a pedal withdrawal response to a
painful stimulus. A pressure-controlled small animal ventilator
set to pressure-assist mode (Harvard Apparatus Ltd, Kent, UK)
was used to ventilate the lungs to normocapnia with 2%
isoflurane. Rats were placed on a heated blanket to prevent
heat loss and rectal temperature was continuously monitored.
An i.v. access cannula was inserted into the tail vein. MitoQ
{[10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)
decyl] triphenylphosphonium} coupled to b-cyclodextrin
was dissolved in saline. MitoE was given as 2-[2-
(triphenylphosphonio) ethyl]-3,4-dihydro-2,5,7,8-tetramethyl-
2H-1-benzopyran-6-ol bromide, also in saline. Melatonin
(N-acetyl-5-methoxytryptamine) was initially dissolved in a
small amount of ethanol then diluted in saline.
Experimental groups
Saline control rats received a 2ml i.v. bolus of saline followed by
an infusion at 3ml kg21 h21. Antioxidant control rats received a
1mlbolus of saline i.v. followedby1.5mmol kg21MitoQorMitoE
ormelatonin in 1ml saline as a bolus and then 1mmol kg21 h21
(3 ml kg21 h21) MitoQ, MitoE, or melatonin as an infusion. LPS/
PepG control rats received a mixture of 0.1 mg kg21 LPS plus 1
mg kg21 PepG in saline as a 1 ml i.v. bolus followed by 1 ml
saline i.v. as a bolus and then an i.v. infusion of saline at 3 ml
kg21 h21. LPS/PepG groupswith antioxidant treatment received
an i.v. bolus of LPS plus PepG in 1ml saline as above, followedby
1.5mmol kg21MitoQ,MitoE, ormelatonin in 1ml saline as an i.v.
bolus and then 1 mmol kg21 h21 MitoQ, MitoE, or melatonin as
an i.v. infusion (3 ml kg21 h21). All rats received the same
volumeof fluid regardless of treatment. After 5 h, the isoflurane
concentration was increased to 5%, blood was removed by
cardiac puncture into a heparinized syringe, a laparotomy
was performed, and lungs, heart, liver, and kidney were
rapidly removed and placed immediately into ice-cold Krebs–
Henseleit buffer (119 mM NaCl, 2.5 mM NaHCO3, 4.7 mM KCl,
1.2 mM MgSO4, 1.18 mM KH2PO4, 11 mM glucose, 0.027 mM
EDTA, 2.5 mM CaCl2) for immediate transport to the laboratory.
All subsequent analyses were undertaken by staff blinded to
the experimental group. A schematic diagram showing the
study design is given in Figure 1.
Liver and renal function
Hepatocellular damage was assessed using plasma alanine
amino transferase (ALT) and aspartate amino transferase
(AST) activity. Renal function was as assessed using plasma
Antioxidant or saline infusionAntioxidant or saline bolus
LPS and PepG or saline bolus
Preparation
Sampling
0 5 h
Baseline Experimental End
Fig 1 Schematic diagram of study design. Preparation¼induction of anaesthesia with isoflurane in a tank, then a tracheostomy with isoflurane
anaesthesia via a nose cone followed by ventilation, venous cannulation, and siting of ECG electrodes. Sampling¼cardiac puncture, laparot-
omy, organ removal, termination.
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creatinine concentration. Plasma samples were assayed in
duplicate on an Advia 2400 Chemistry System (Siemens
Healthcare Diagnostics, Deerfield, IL, USA). ALT and AST
were measured enzymatically15 and creatinine was mea-
sured colorimetrically.16
Isolation of mitochondria from the liver
Liver pieces were placed in fresh ice-cold Krebs–Henseleit
buffer to remove all traces of blood, then homogenized
using a Teflon pestle in ice-cold mitochondrial isolation
buffer (10 mM TRIS-MOPS, pH 7.4, 10 mM EGTA-TRIS, 200
mM sucrose). Cell debris was removed by centrifugation at
48C. The supernatant was then further centrifuged and the
pellet containing the heavy mitochondrial fraction was
washed with ice-cold respiration buffer (125 mM KCl, 10
mM TRIS–MOPS pH 7.4, 1 mM EGTA–TRIS, 1 mM KH2PO4).
Protein content was measured using the Bradford assay
(BioRad, Herts, UK) and mitochondria were used within 3 h.
Similar mitochondrial yields were seen in all samples.
Mitochondrial respiration
Mitochondrial respiration was measured using a calibrated
Clark-type oxygen electrode and oxygen consumption
recorded using Picolog for Windows, v5.14.6 (Pico Technology
Ltd, Cambs, UK) at 378C for 20 min in air-saturated respiration
media. Respiration experiments were initiated by adding 1 mg
ml21 isolated mitochondria to respiration buffer. Oxygen con-
sumption due to state 1 respiration was recorded for several
minutes before the addition of either 5 mM glutamic acid
plus 2.5 mM malic acid (complexes I, II, III, IV) or 5 mM suc-
cinic acid plus 2 mM rotenone (complexes II, III, IV), and
oxygen consumption was again recorded. Then, 100 mM
ADP was added to initiate state 3 respiration. State 3 respir-
ation, followed by state 4 respiration (depletion of ADP), was
recorded before the final addition of the protonophore
carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP,
100 nM) to provide uncoupled respiration, independent of
ADP. Respiration due to complex IV (cytochrome oxidase)
activity was determined after addition of antimycin A, ascorbic
acid, and N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD).
Ascorbic acid maintains TMPD (an artificial electron donor)
in a reduced state and the TMPD donates electrons to cyto-
chrome c. The addition of sodium azide to inhibit cytochrome
c enabled measurement of non-mitochondrial oxygen
consumption.17
Oxidative damage
Plasma lipid hydroperoxides and liver protein carbonyl levels
were determined in duplicate using commercially available
assays (Cayman Chemical Company, Houston, TX, USA).
Liver samples were washed and homogenized, centrifuged,
and any contaminating nucleic acid was precipitated using
streptomycin sulphate before assay. Protein levels were
measured using the Bradford assay.
Cytokines
Interleukin-6 (IL-6) and IL-10 were measured in duplicate in
plasma using commercially available enzyme rat immuno-
assay kits (R&D Systems Europe, Oxford, UK).
Statistical analysis
No assumptions were made about data distribution, and data
are presented as median, inter-quartile, and full range. Statis-
tical analysis was undertaken using the Analyse-ItTM add-in
for Microsoft Excel. Data sets between the LPS/PepG groups
were compared using the Kruskal–Wallis with the Mann–
Whitney U-test for post hoc analysis. Basal and maximal
heart rate within treatment groups were compared using
the Wilcoxon signed-ranks test for paired data. A P-value of
,0.05 was considered to be significant.
Results
Rat model
We used a non-recovery, moderately fluid-resuscitated,
anaesthetized model of acute sepsis using a combination
of LPS from Gram-negative bacteria, and PepG from Gram-
positive bacteria. This model has previously been shown to
result in a reproducible acute inflammatory response, with
increased cytokines, oxidative stress, mitochondrial dysfunc-
tion, and early biochemical changes associated with organ
dysfunction,12 14 similar to the changes seen in human
sepsis. Around 25% of rats given LPS/PepG without antioxi-
dants died under anaesthesia before the end of the experi-
mental period; these rats were not included in the analysis
and were replaced by additional animals. No animals died
in the other experimental groups.
Heart rate increased in the LPS/PepG control rats such that
the maximum heart rate was significantly higher than the
basal heart rate (Table 1). ALT and AST activity in plasma
were markedly elevated in LPS/PepG control rats, compared
with saline control rats, indicative of hepatocellular
damage (Fig. 2). Plasma creatinine levels were also elevated
Table 1 Basal and maximum heart rates [median (range)]. *Significantly increased compared with basal heart rate (Wilcoxon signed-ranks test
for paired data, P¼0.016). LPS/PepG, lipopolysaccararide and peptidoglycan G
Saline control LPS/PepG control LPS/PepG1MitoE LPS/PepG1MitoQ LPS/PepG1melatonin
Basal heart rate (beats min21) 318 (314–346) 315 (309–346) 322 (249–350) 355 (316–405) 309 (300–351)
Max heart rate (beats min21) 403 (354–436) 420* (340–509) 364 (378–388) 406 (329–527) 380 (325–450)
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by LPS/PepG treatment (Fig. 2), indicating renal damage, and
liver protein carbonyl and plasma lipid hydroperoxide con-
centrations (Fig. 3) were increased indicating oxidative
damage. Plasma IL-6 and IL-10 were also higher in LPS/
PepG control rats than in saline control rats (Fig. 4) and mito-
chondrial respiration was decreased (Fig. 5).
Effects of MitoE, MitoQ, or melatonin alone
MitoE, MitoQ, or melatonin control rats had similar plasma
biomarker levels to saline control rats (Table 2). Heart rates
did not change in these animals (data not shown).
Effect of antioxidants on organ function, oxidative
stress, and cytokines
Plasma ALT activity was lower in rats given LPS/PepG that
were subsequently treated with MitoE, MitoQ, or melatonin,
than in LPS/PepG control rats (Fig. 2A). AST and creatinine
were decreased by antioxidants but were significantly lower
only in those rats treated with melatonin (Fig. 2B and C).
The maximum heart rate did not increase and was not differ-
ent from basal heart rate in the LPS/PepG rats treated with
MitoQ, MitoE, or melatonin (Table 1). The LPS/PepG-treated
rats given MitoE, MitoQ, or melatonin had significantly
lower levels of liver protein carbonyls (Fig. 3A) and plasma
lipid hydroperoxides (Fig. 3B). The increase in plasma IL-6
levels in rats given LPS and PepG was blunted by MitoQ,
MitoE, or melatonin treatment (Fig. 4A). IL-10 levels were
higher in LPS/PepG rats treated with MitoE than in those
given LPS/PepG without antioxidants, but neither MitoQ nor
melatonin had any effect on IL-10 (Fig. 4B).
Effect of antioxidants on mitochondrial function
Mitochondrial respiration in the liver was measured as the
number of ATP molecules made as electrons pass along
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the respiratory chain to oxygen (expressed as the ATP:O
ratio). The ATP:O ratio with glutamate and malate as sub-
strate (complexes I, II, III, and IV) and that with succinate
plus rotenone (complexes II, II, and IV) were lower in liver
mitochondria from LPS/PepG control rats than saline control
animals (Fig. 5A and B). Complex IV respiration was also
markedly lower in the LPS/PepG control rats than saline
control rats (Fig. 5C).
LPS/PepG rats treated with either MitoQ or MitoE had
ATP:O ratios similar to saline control animals when either glu-
tamate/malate or succinate was used as substrate (Fig. 5A
and B). Melatonin treatment increased the ATP:O ratio with
glutamate/malate but just failed to reach significance with
succinate (Fig. 5B). Treatment of LPS/PepG rats with either
MitoE, MitoQ, or melatonin augmented complex IV activity
compared with LPS/PepG control rats (Fig. 5C). The respiratory
control index (RCI), the ratio of the rate of mitochondrial
oxygen consumption in respiratory state 3 to that in respira-
tory state 4, is a measure of the efficiency of energy coupling,
used for diagnosis of mitochondrial defects. The RCI was
similar in all rat groups with either glutamate/malate or
succinate as substrate, suggesting that there was no
difference in terms of experimentally generated mitochon-
drial dysfunction between treatment groups during assay
and that mitochondria were not ‘uncoupled’ (data not
shown).
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Discussion
We have shown that in an acute model of LPS/PepG-induced
sepsis, characterized by inflammation, organ dysfunction,
and mitochondrial damage, treatment with MitoQ, MitoE,
or melatonin had broadly similar effects, including decreased
biochemical markers of early organ dysfunction, decreased
oxidative stress, decreased pro-inflammatory cytokine
responses, and less mitochondrial dysfunction.
Although the Surviving Sepsis Campaign, a performance
improvement effort by hospitals across Europe, South
America, and the USA has improved outcomes, the mortality
from sepsis remains high.1 ROS contribute to inflammatory
responses by activating key signalling pathways including
the redox sensitive transcription factor pathway of nuclear
factor kB (NFkB) and the inflammasome.18 19 Mitochondria
produce more than 90% of the body’s energy needs in the
form of ATP, via oxidative phosphorylation. The majority of
ROS production occurs within mitochondria during ATP
generation. Also, being the major source of intracellular
ROS, mitochondria are a major target of ROS-mediated
damage.2 Mitochondrial ROS (mtROS) are important for cellu-
lar signalling but can also cause cell damage, and so are
tightly regulated by endogenous antioxidant scavenging
systems that limit damage. Under conditions of stress or
disease, ROS production is increased, antioxidant protection
is decreased, mitochondrial damage occurs, and inflamma-
tion increases, creating a vicious cycle. The loss of enzyme
function in the electron transport chain, mitochondrial dys-
function, and impaired ATP generation then occurs, with per-
oxidation of cardiolipin, dissociation of cytochrome c, further
reduction in ATP production and more ROS generation.3 This
self-sustaining and amplifying cycle between ROS gener-
ation, inflammatory responses, and mitochondrial impair-
ment contributes to organ failure in patients with sepsis.4 5 20
Since mitochondria are the main source and target of ROS,
antioxidants that act in mitochondria might be more effect-
ive than antioxidants that act generally.8 9 mtROS have been
shown to drive inflammatory cytokine responses via both
inflammasome-dependent and -independent mechanisms
acting together with NFkB to regulate several cytokines in-
cluding IL-1b and IL-6.18 19 We have shown that antioxidants
that act within mitochondria reduce IL-1b and IL-6 levels
and decrease NFkB activation in LPS/PepG-treated endothe-
lial cells.11–13 Decreased NFkB activation has also been
shown in septic animals treated with melatonin.21
MitoQ, MitoE, and melatonin have differing antioxidant
actions but all act within mitochondria. MitoQ consists of
a lipophilic cation, triphenylphosphonium (TPP), attached
to ubiquinone by a saturated 10-carbon alkyl chain. Once
inside mitochondria, the ubiquinone is reduced to its active
ubiquinol form by complex II.8 22 MitoE in contrast comprises
a-tocopherol (vitamin E) attached to the TPP cation but
with a shorter, 2-carbon alkyl chain. In addition to having dif-
ferent structures, MitoQ and MitoE also act in different parts
of the mitochondrion and thus might be expected to have
differing effects.T
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Both superoxide and nitric oxide have crucial roles in the
mechanisms of mitochondrial damage in sepsis through for-
mation of peroxynitrite, resulting in suppression of mitochon-
drial respiration, with reduced ATP synthesis, inhibition of
complexes I and II, and damage to mitochondrial DNA.23–25
Mitochondrial antioxidants including MitoQ/E have been
shown to reduce peroxynitrite formation, nitrotyrosination
of proteins, and alleviate mitochondrial dysfunction in
several studies.24–26 The antioxidant effects of melatonin
and its metabolites occur by several mechanisms including
direct effects on free radicals and interactions with other
toxic species including hydrogen peroxide, nitric oxide, and
peroxynitrite.9–11 26–28 The mitochondrial antioxidants
used in our study might protect against mitochondrial dys-
function via effects on superoxide, nitric oxide, peroxynitrite
itself, or a combination. Melatonin also up-regulates en-
dogenous antioxidants throughout the cell,11 29 30 whereas
this has not been described for MitoQ or MitoE.
Despite differing mechanisms, the effects of MitoQ, MitoE,
and melatonin were broadly similar in our study. Oral, i.p., or
i.v. administration of MitoQ or MitoE results in accumulation
in major organs in rats and mice, including the heart, liver,
and kidneys.31 32 Exogenous melatonin accumulates
throughout the cell, with levels depending on the dose,
highest in the cell membrane and mitochondria.33
We found that mitochondrial respiratory function was
decreased in mitochondria from the livers of rats given LPS/
PepG without antioxidants. The liver is highly metabolic
with high yields of mitochondria and mitochondrial ultra-
structural changes in the liver of patients who died from
sepsis have been reported.34 Previous studies in intact
peripheral leucocytes from patients in the early stages of
sepsis also showed decreased mitochondrial oxygen con-
sumption and complex activity similar to that reported
here.20 35 36 The present study showed that antioxidant
treatment returned mitochondrial respiration towards
normal in rats given LPS and PepG. MitoE has also been
shown to protect against loss of complex IV activity in
hearts of septic rats32 and melatonin interacts with
enzymes of the electron transport chain and oxidative phos-
phorylation with increased transcription of complex IV
enzymes correlating with complex IV activity.35 Complex IV
(cytochrome c oxidase activity) is essentially an indicator of
mass and health of mitochondria and is commonly used as
a predictor of ‘mitochondrial fitness’. Maj and colleagues37
recently developed a live cell screening tool and found that
many compounds increase complex IV activity either via ac-
tivation of peroxisome proliferator-activated (PPAR) receptors
or the protein kinase A pathway. It remains speculative as to
whether the antioxidants used in our study acted via these
mechanisms, although melatonin is known to be a potent
PPAR receptor activator.
In this study, we found that i.v. MitoQ, MitoE, or melatonin
after administration of LPS/PepG resulted in improvements in
measures of organ dysfunction, lower IL-6 levels, less oxidative
damage, and improved mitochondrial function, concurring
with our previous in vitro and in vivo studies.11–13 Early relative
levels of IL-6 and IL-10 have been suggested to be crucial
factors determining the severity of sepsis.36 Global mitochon-
drial dysfunction associated with NFkB activation, and elevated
IL-6 and lipid peroxidation products in plasma, has been
reported in patients, suggesting that mitochondrial dysfunc-
tion is an early event in sepsis.20 Therapies designed to inter-
fere with signalling pathways are likely to be most effective
at the early stages of sepsis.
In agreement with our study, treatment of rats with a
single oral dose of MitoE was recently reported to protect
the heart against damage caused by sepsis induced by intra-
tracheal injection of Streptococcus pneumoniae, including
preservation of mitochondrial structure and function, main-
tenance of mitochondrial membrane potential, preservation
of mitochondrial respiration, and reduction in oxidative
stress.32 In the same study, pro-inflammatory cytokines in-
cluding IL-6 were lower in animals treated with MitoE, but
IL-10 was not reported.32 We found that IL-10 levels were
higher in septic rats given MitoE, but not MitoQ or melatonin,
and further studies are needed to dissect the mechanism of
this effect. Studies in cells, rats, and patients with sepsis
show an exponential relationship between IL-6 and IL-10
levels, and it is possible that the effects of MitoE on IL-10
are mediated via effects on IL-6.36
Other studies using an acute LPS rat model have reported
that IL-10 levels were higher in lung tissue, peritoneal fluid,
and serum of rats treated with melatonin,21 38 although
the doses of melatonin given were approximately three-fold
higher than in our study. Another recent study showed
decreased tissue oxidative stress in septic rats treated with
slow-release melatonin delivered using nanoparticle car-
riers,39 but neither cytokine levels nor mitchondrial function
were reported. In addition, a recent small clinical trial
showed that a single oral dose of melatonin resulted in
lower liver transaminase activity in patients undergoing
major liver resection.40
We acknowledge several limitations of our study. Although
animal models never replicate exactly what happens in
patients, LPS/PepG given i.v. results in similar haemodynamic
and cytokine changes as seen in acute early human sepsis.
Animal models remain the only way in which proof-of-concept
studies to assess the potential of novel therapies can be
undertaken. We administered antioxidants after LPS/PepG,
rather than pre-treating the rats, and we gave the drugs i.v.
rather than i.p. to better reflect the clinical situation. LPS
and PepG have been shown to synergize and amplify the in-
flammatory response.14 Mitochondrial dysfunction can be
assessed in a variety of ways; the best is thought to be mea-
sures of respiration. Intact cells have been used in some
studies, but the cell permeabilization to achieve this intro-
duces its own problems and combinations of methods are
most useful. The findings in our rat model mirror changes in
mitochondria seen in cells from patients with sepsis, and so
we would argue that such measures give at least a suggestion
of the effects likely to be seen in vivo.20
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Inhalation anaesthesia with isoflurane is an increasingly
popular method for general anaesthesia for biomedical re-
search in rats.32 41 It has some advantages over injectable
agents including reduced animal handling requirements, a
wide safety margin, and good control of anaesthesia. Isoflur-
ane anaesthesia is protective against an ischaemic insult as
both a pre- and post-conditioning agent. A brief period of iso-
flurane anaesthesia resulted in attenuated inflammatory
responses and improved survival rates in septic rats.41
Longer durations of isoflurane anaesthesia have been sug-
gested to be neurotoxic but prolonged anaesthesia of
young rats with isoflurane had no effect on adult hippocam-
pal cell proliferation.42 It is not known what effects isoflurane
had in our study, but all animals did receive identical isoflur-
ane anaesthesia.
Although MitoQ has been through phase I trials and there
have also been phase II trials in other disease conditions,43
phase I trials of MitoE have not been conducted. There
have been clinical studies of low doses (1–5 mg) of exogen-
ous melatonin in critically ill patients,44 and melatonin has
been administered to patients in other disease conditions
at larger doses resulting in decreased cytokine and lipid per-
oxide levels.45 Melatonin has also been given to critically ill
neonates.46
In summary, we have shown that MitoQ, MitoE, and mela-
tonin are protective in a rat model of acute inflammation,
oxidative stress, and mitochondrial dysfunction. This
proof-of-concept study suggests that antioxidants that
protect mitochondria might be beneficial in patients with
sepsis. We propose that melatonin might be the most ac-
cessible agent for clinical studies at present.
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